Peterson Wealth Services Increases Stock Holdings in Lantheus Holdings, Inc. $LNTH

Peterson Wealth Services increased its position in Lantheus Holdings, Inc. (NASDAQ:LNTH) by 3,160.5% in the first quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 6,684 shares of the medical equipment provider’s stock after acquiring an additional 6,479 shares during the quarter. Peterson Wealth Services’ holdings in Lantheus were worth $507,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors have also bought and sold shares of the company. Smartleaf Asset Management LLC lifted its stake in Lantheus by 63.3% in the 4th quarter. Smartleaf Asset Management LLC now owns 508 shares of the medical equipment provider’s stock worth $34,000 after purchasing an additional 197 shares in the last quarter. Parallel Advisors LLC grew its position in shares of Lantheus by 122.6% during the 4th quarter. Parallel Advisors LLC now owns 541 shares of the medical equipment provider’s stock valued at $36,000 after purchasing an additional 298 shares in the last quarter. Osterweis Capital Management Inc. purchased a new position in shares of Lantheus during the 2nd quarter valued at $36,000. Los Angeles Capital Management LLC bought a new position in shares of Lantheus in the fourth quarter worth $39,000. Finally, Farther Finance Advisors LLC increased its holdings in shares of Lantheus by 71.4% in the fourth quarter. Farther Finance Advisors LLC now owns 660 shares of the medical equipment provider’s stock worth $44,000 after purchasing an additional 275 shares during the period. Institutional investors own 99.06% of the company’s stock.

Analysts Set New Price Targets

LNTH has been the subject of several research analyst reports. B. Riley Financial lifted their price objective on Lantheus from $97.00 to $129.00 and gave the company a “buy” rating in a research note on Thursday. Citigroup restated an “outperform” rating on shares of Lantheus in a research note on Friday, May 8th. Truist Financial reaffirmed a “buy” rating and issued a $115.00 price target (up from $98.00) on shares of Lantheus in a report on Monday, May 11th. Mizuho boosted their price objective on Lantheus from $100.00 to $115.00 and gave the stock an “outperform” rating in a report on Wednesday, May 27th. Finally, Wall Street Zen cut shares of Lantheus from a “strong-buy” rating to a “buy” rating in a research report on Saturday, May 9th. Eight analysts have rated the stock with a Buy rating and three have assigned a Hold rating to the company. According to MarketBeat, the company has an average rating of “Moderate Buy” and a consensus price target of $108.29.

Lantheus Stock Down 0.7%

LNTH opened at $105.99 on Friday. The stock has a market cap of $6.90 billion, a PE ratio of 25.54 and a beta of -0.06. The company has a quick ratio of 2.64, a current ratio of 2.83 and a debt-to-equity ratio of 0.47. Lantheus Holdings, Inc. has a 52 week low of $47.25 and a 52 week high of $111.86. The business’s fifty day simple moving average is $100.22 and its 200 day simple moving average is $82.74.

Lantheus (NASDAQ:LNTH) last issued its quarterly earnings results on Thursday, May 7th. The medical equipment provider reported $1.46 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.25 by $0.21. Lantheus had a return on equity of 29.32% and a net margin of 18.05%.The firm had revenue of $377.33 million during the quarter, compared to analyst estimates of $354.48 million. During the same quarter in the previous year, the company posted $1.53 earnings per share. The company’s revenue was up 1.2% compared to the same quarter last year. Lantheus has set its FY 2026 guidance at 5.000-5.250 EPS. As a group, research analysts expect that Lantheus Holdings, Inc. will post 4.49 earnings per share for the current fiscal year.

Lantheus Profile

Lantheus Holdings, Inc is a global life sciences company specializing in the development, manufacturing and commercialization of diagnostic imaging agents and radiopharmaceuticals. Headquartered in North Billerica, Massachusetts, Lantheus focuses on products that enhance the detection and management of cardiovascular and oncologic diseases. The company’s portfolio spans ultrasound-enhancing agents, molecular imaging tracers for positron emission tomography (PET), and emerging theranostic platforms designed to pair diagnostic and therapeutic applications.

The diagnostic imaging segment includes ultrasound contrast agents such as DEFINITY® (perflutren lipid microsphere) and Sonazoid® (perflubutane), which improve the visualization of cardiac structures and blood flow.